Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study investigating the efficacy of Velcade, rituximab, cyclophosphamide, and Decadron (VRCD regimen) in front-line therapy of patients with low-grade non-Hodgkin's lymphoma.

Trial Profile

Phase II study investigating the efficacy of Velcade, rituximab, cyclophosphamide, and Decadron (VRCD regimen) in front-line therapy of patients with low-grade non-Hodgkin's lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2018

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 10 Jan 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
    • 10 Jan 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top